Du er her: Forside > Oslo Axess - Unoterte - Warrants - Derivater > Hofseth Biocare - vendepunkt Q3 2017?
Hofseth Biocare - vendepunkt Q3 2017?
Savepig
17:22
10.10.2017
#506

http://www.hofsethbiocare.com/investors/

Vision and key objectives
Hofseth BioCare´s key objective is to provide high value added biomarine ingredients for human applications. Through innovative production technology and logistics, we preserve the quality of protein, calcium and oil extracted from fish. This technology is proprietary to our company.

Products that previously could only be used for animal feed can now be made suitable for human consumption and pharmaceuticals. We are thus contributing to efficient use of marine resources.

Background
Hofseth BioCare is a Norwegian biomarine company with roots back to year 2000. Our proprietary technology is based upon a new method for fully controlled by-product refinement up to high-end products. After 12 years of R&D, testing and documentation, the company's proprietary enzymatic hydrolysis-process converts by-products to sustainable value-added products. Hofseth BioCare's products are sustainable and traceable. There is a growing demand for proteins in the world and providing sustainable high quality products to the market is the main goal for Hofseth BioCare.



Endret 10.10.2017 17:23 av Savepig
Savepig
17:26
10.10.2017
#507

Spennende nyhet i dag:

http://www.hegnar.no/Nyheter/Boers-finans/2017/10/Hofseth-Biocare-venter-aatte-ganger-hoeyere-inntekter

Hofseth Biocare venter åtte ganger høyere inntekter

Hofseth Biocare er ute med en finansiell oppdatering. Ifølge en finansiell oppdatering tirsdag, venter biotech-selskapet Hofseth Biocare å rapportere om inntekter på 28 millioner kroner i tredje kvartal.

Det tilsvarer i så fall en økning på neste åtte ganger fra tilsvarende kvartal i fjor da inntektene beløp seg til 3,6 millioner kroner.

Det opplyses at selskapets kontantbalanse var på om lag 30 millioner kroner ved utgangen av tredje kvartal.

Selskapet legger frem kvartalsrapporten 15. november.

http://www.hofsethbiocare.com/investors/stock-exchange-notices/?press_id=2140914×tamp=201710
Savepig
17:26
10.10.2017
#508

Mine tanker:

TL;DR: Cash balance i Hofseth økt med 12 millioner på 3 måneder? Wtf?

Det er en del trekk ved HBC som er ganske spennende.

Pent innsidekjøp i våres:
http://www.newsweb.no/newsweb/search.do?messageId=422721

Topp 50 har sittet så godt som helt i ro gjennom hele det kursraset som har vært i det siste.

Så kan man sammenligne dagens melding med Q2 rapporten:
http://www.hofsethbiocare.com/investors/stock-exchange-notices/?press_id=2129208×tamp=201708

http://www.hofsethbiocare.com/investors/stock-exchange-notices/?press_id=2140914×tamp=201710

Cash flow from operations during the second quarter was negative by NOK 9.6m compared to negative NOK 36.1m in the same quarter last year.

Hofseth BioCare had operating revenues of NOK 5.5m (8.2m) in the second quarter of 2017.

Based on preliminary figures for the Third Quarter 2017, Hofseth BioCare ASA (HBC) management expects to report group revenues of approximately NOK 28m for the quarter, compared to NOK 3.6m in the same quarter 2016.

Cash and cash equivalents at the end of H1: 18 162

The cash balance by the end of Q3 was approx. NOK 30m. HBC will report 3rd quarter 2017 financial results 15th November 2017.

Altså har cash balance økt med 12 millioner på tre måneder? Hva foregår?

Spekulativt: Kan vi vente oss et saftig innsidekjøp i morgen?
Savepig
13:23
11.10.2017
#510

Lurte i går på om det ville komme et innsidekjøp i dag, var vel nesten forventet.

Sjefen skuffer ikke:

Roger Hofseth AS, et selskap 100% eiet av Roger Hofseth som er administrerende
direktør i Hofseth BioCare ASA, har i dag 11.10.2017 kjøpt 152.299 aksjer til
snittkurs 1,6026 pr aksje. Etter dette har Roger Hofseth AS 37.400.000 aksjer
tilsvarende 16,02% av de utestående aksjene i Hofseth BioCare ASA.
Savepig
19:42
31.10.2017
#519

Det er en rimelig stram eiersits i dette selskapet! Topp 20 sitter på 88% av aksjene.

Største eier er et fond:

https://agfundernews.com/new-aquaculture-pe-fund-seeking-small-pearls-in-sector-invests-in-fish-waste-by-products003.html
Savepig
22:17
06.11.2017
#528

Pen spike i dag.

Nå er jo market cap allerede ganske høy i forhold til earning i Hofseth, så blir litt spennende å se hvor høyt dette egentlig kan gå.
Savepig
13:37
07.11.2017
#530

HBC:INNGÅTT NY FINANSIERINGSAVTALE PÅ 35M
12:47

Oslo (TDN Finans): Hofseth BioCare har i dag inngått en ny finansieringsavtale på 35 millioner kroner, ifølge en melding tirsdag.

Økte salgs- og produksjonsvolumer etter andre kvartal har krevd høyere arbeidskapitalbehov og selskapet har sikret finansiering av lager og utestående fordringer med denne avtalen, opplyses det i meldingen.

Avtalen er effektiv fra og med i dag, og er gjort til markedsbetingelser.



HH, finans@tdn.no
TDN Finans, +47 21 95 60 70

© TDN delayed
Savepig
07:57
15.11.2017
#537

Da er Q3 for Hofseth Biocare ute:

Hofseth BioCare ASA (HBC) had operating revenues of NOK 92.1m (17.1m) in the first nine months of 2017, EBITDA of NOK 17.1m (-105.6m) and EBIT of NOK 0.6m, compared to negative 118.6m in the corresponding period 2016.

In the third quarter, the Company had revenues of NOK 27.9m (3.6m). Total operating expenses amounted to NOK 39.3m (49.2m) in the period which resulted in an EBITDA of negative NOK 6.3m (negative NOK 41.2m).

Cash flow from operation activities during the third quarter was positive by NOK 7.3m compared to negative NOK 17.7m in the same quarter last year. Cash and cash equivalents increased by NOK 11.6m during the quarter, leaving total holding of cash and cash equivalents at NOK 29.8m by the end of the period.

Total equity amounted to NOK 49.9m (NOK 77.1m) giving an equity ratio of 33.1% (40.4 %) for the group.

Highlights:
Mr. Roger Hofseth elected new CEO in August, and Mr. Ola Holen steps up as interim Chairman of the Board in September.
Record revenues after completing the production lines at the Midsund plant and high delivery schedules of all four products on existing and new long-term contracts.

Research show that HBCs CalGo is 100% calcium hydroxyapatite microcrystalline form of calcium. This is considered the best form of calcium for absorption and incorporation. Orders received on CalGo during the quarter show promising future for this product.

Finished first phase in our major research project, with the Lucille Packard Hospital at Stanford University, into the use of SPH in treating ultra-low birthweight babies and the impact of SPH on bile acid and protein digestion, and biological effects.

HBC produced a total of 665 tons of finished products during the third quarter of 2017, up 10 per cent from the last quarter.

Our mission is to deliver high quality ingredients to the market, and we now finally are starting to see the first results from all the work we have put down. Hofseth BioCare will continue to ramp up production during the fourth quarter to increase gross margins and aim to deliver steady positive EBITDA in the near future.
We expect to reach full capacity in the beginning of 2018, says Roger Hofseth, CEO of Hofseth BioCare.

https://www.nordnet.no/mux/web/analys/nyheter/visaNyhet.html?itemid=294590009&sourcecode=hugin
Savepig
09:24
15.11.2017
#538

Gått grundig gjennom rapporten nå.

Det virker helt sjanseløst å starte pressemeldingen med å fokusere på revenue for 2017 sett under ett, gitt at 52 millioner er en engangsinntekt fra restrukturering av bygningsmassen. (Kjøpt av en storeier og tilbakeleid.)

Veksttallene virker gode, men lønnsommheten tyder på at man fremdeles venter på den store saliggjørende kontrakten av å selge til menneskefor:

Q3:
Revenue: 27923
Finished goods production: 665

Q2:
Revenue: 5505
Finished goods production: 549

Q1:
Revenue: 6444 (justert)
Finished goods production: 561
Savepig
14:06
25.06.2018
#644

Aksjen stiger stille og rolig, eierne sprøyter enda mer penger inn i selskapet. Sånn går no dagan.
highlander
16:24
06.09.2018
#12189

Hofseth Biocare har levert inn en søknad om et foreløpig patent i USA på som omfatter resultatene av en ny studie publisert i tidsskriftet Functional Foods som tar for seg ulike behandlinger via ProGo som er selskapets lakseproteinhydrolysatløsning:

06/09-2018 09:05:20: (HBC.OAX) Hofseth Biocare ASA: New study and US provisional patent filed on regulation of oxidative protective genes in human cells with ProGo for treatment of IBD, such as ulcerative colitis and Crohn's

An invitro study on the regulation of oxidative protective genes in human gingival and intestinal epithelial cells after treatment with salmon protein hydrolysate peptides has been published in the journal Functional Foods in Health and Disease (2018; 8(8): 353-366). HBC has also recently filed a provisional US patent covering these results.

This study measured the up/down regulation of 84 oxidative protective genes within human gingival epithelial cells and human intestinal epithelial cells when treated with varying concentrations of ProGo® (HBC salmon protein hydrolysate) solution.

The regulation of oxidative stress-related genes as a possible mechanism that can confer cyto-protection to tissues exposed to oxidative injury has been the subject of investigation by many researchers.

While molecular oxygen is essential for the survival of almost all eukaryotes, its processing under physiological conditions generates reactive oxygen species (ROS) such as hydrogen peroxide, superoxide, peroxy nitrite, and hydroxyl radicals, as metabolic by-products. In the absence of an adequate defense mechanism, the accumulation of ROS and other electrophiles leads to cell membrane and DNA damage, mutagenicity, degeneration of tissues, premature aging, apoptotic cell death, and cancers. To combat excess ROS, cells have developed an array of inducible defensive gene activations which results in a neutralization of the oxidative stress, reduced ROS, and thereby increased cell survival.

Results from this study conclude that ProGo® powder contains bioactive peptides that changes the regulation of several oxidative protective genes in two different human epithelial cells. The unusually high number of genes shown to be impacted may be a direct result of the over 250 peptides of certain molecular weights in ProGo® developed by HBC over the last ten years, that could act as gene modulators.

Three genes also showed a dose-dependent response to ProGo®, the FTH1, HMOX1 and ALOX12 genes. The upregulation in the HMOX1 gene, particularly in intestinal epithelial cells, is being used by HBC to guide the development of a functional food that can confer a protective effect on the gastrointestinal tract. Such a product may be used, in conjunction with medical treatment, for the control of Inflammatory Bowel Disease (IBD), such as ulcerative colitis, enterocolitis and Crohn's disease.
Varsling på tema     Varsling på stikkord




StockTalk er en tjeneste levert av Kreateam Consult AS. Orgnr. 911 839 806 MVA
Adresse: Postboks 39 Holmlia, 1201 Oslo. Email: st@stocktalk.no Tlf. 40 07 31 70
Kontakt oss | Hjelp | Regler | Sett som startside | Legg til favoritter